Emerald Mutual Fund Advisers Trust Has $21.84 Million Position in LivaNova PLC (NASDAQ:LIVN)

Emerald Mutual Fund Advisers Trust decreased its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 10.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 471,674 shares of the company's stock after selling 56,438 shares during the period. LivaNova comprises approximately 1.3% of Emerald Mutual Fund Advisers Trust's investment portfolio, making the stock its 19th biggest holding. Emerald Mutual Fund Advisers Trust owned approximately 0.87% of LivaNova worth $21,843,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Northern Trust Corp raised its stake in LivaNova by 11.2% in the fourth quarter. Northern Trust Corp now owns 703,019 shares of the company's stock valued at $32,557,000 after purchasing an additional 70,630 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of LivaNova by 163.6% in the 4th quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company's stock valued at $25,303,000 after buying an additional 339,139 shares in the last quarter. Tri Locum Partners LP bought a new stake in shares of LivaNova during the 4th quarter worth approximately $4,617,000. Aquatic Capital Management LLC raised its position in LivaNova by 28.7% during the fourth quarter. Aquatic Capital Management LLC now owns 22,260 shares of the company's stock valued at $1,031,000 after purchasing an additional 4,960 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of LivaNova in the 4th quarter valued at $2,772,000. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Trading Down 0.0 %

Shares of NASDAQ:LIVN traded down $0.01 during mid-day trading on Friday, hitting $36.78. The company had a trading volume of 925,924 shares, compared to its average volume of 611,981. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova PLC has a one year low of $32.48 and a one year high of $64.48. The firm has a fifty day moving average price of $38.07 and a 200 day moving average price of $45.75. The company has a market capitalization of $2.00 billion, a PE ratio of 87.57 and a beta of 0.90.

Analyst Upgrades and Downgrades

LIVN has been the topic of a number of recent analyst reports. Wolfe Research cut LivaNova from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a "buy" rating and set a $64.00 target price on shares of LivaNova in a research report on Monday, March 17th. Mizuho reduced their price target on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. Stifel Nicolaus lowered their price objective on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Finally, StockNews.com upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a report on Tuesday, March 25th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, LivaNova presently has a consensus rating of "Buy" and a consensus price target of $61.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.